Baidu
map

Diabetes Care:甘精胰岛素轻度降低动脉粥样硬化风险

2013-04-11 高廉 编译 医学论坛网

    对于心血管疾病患者和/或糖代谢障碍伴心血管事件风险者,甘精胰岛素治疗可使患者血糖水平恢复正常,并轻度延缓颈动脉内膜中层厚度(CIMT)增加,而每日补充n-3多不饱和脂肪酸(n-3FA)则无此效果。2013年4月5日在线发表于《糖尿病护理》的一项研究得出上述结论。   研究采用随机多中心2 × 2析因设计,共纳入1184例罹患心血管疾病或存在心血管风险的患者,所有患者均伴发空腹

甘精胰岛素动粥风险
 

  对于心血管疾病患者和/或糖代谢障碍伴心血管事件风险者,甘精胰岛素治疗可使患者血糖水平恢复正常,并轻度延缓颈动脉内膜中层厚度(CIMT)增加,而每日补充n-3多不饱和脂肪酸(n-3FA)则无此效果。2013年4月5日在线发表于《糖尿病护理》的一项研究得出上述结论。

  研究采用随机多中心2 × 2析因设计,共纳入1184例罹患心血管疾病或存在心血管风险的患者,所有患者均伴发空腹血糖受损(IFG)、糖耐量异常或合并早期2型糖尿病。受试者接受甘精胰岛素治疗(目标为空腹血糖水平≤5.3 mmol/L [95 mg/dL])或标准降糖干预,全程双盲服用1g n-3FA或安慰剂。

  研究主要终点为颈总动脉、颈动脉分叉部以及内颈动脉部所有部位CIMT年变化率。次级终点为颈总动脉、颈总动脉+分叉部CIMT年均最大增加率。由基线始每年行超声检查,中位随访时间4.9年。

  主要终点结果,甘精胰岛素组与标准治疗组相比可减轻CIMT,但差异无统计学意义(P = 0.145);次级终点两组差异明显(颈总动脉CIMT差异0.0033 ± 0.0017 mm/年[P = 0.049],颈总动脉+分叉部CIMT差异0.0045 ± 0.0021 mm/年[P = 0.032])。 

抑郁相关的拓展阅读:


Effect of Insulin Glargine and n-3FA on Carotid Intima-Media Thickness in People With Dysglycemia at High Risk for Cardiovascular Events
The Glucose Reduction and Atherosclerosis Continuing Evaluation Study (ORIGIN-GRACE)
OBJECTIVES

To evaluate the effects of insulin glargine and n-3 polyunsaturated fatty acid (n-3FA) supplements on carotid intima-media thickness (CIMT).
RESEARCH DESIGN AND METHODS
We enrolled 1,184 people with cardiovascular (CV) disease and/or CV risk factors plus impaired fasting glucose, impaired glucose tolerance, or early type 2 diabetes in a randomized multicenter 2 × 2 factorial design trial. Participants received open-label insulin glargine (targeting fasting glucose levels ≤5.3 mmol/L [95 mg/dL]) or standard glycemic care and double-blind therapy with a 1-g capsule of n-3FA or placebo. The primary trial outcome was the annualized rate of change in maximum CIMT for the common carotid, bifurcation, and internal carotid artery segments. Secondary outcomes were the annualized rates of change in maximum CIMT for the common carotid and the common carotid plus bifurcation, respectively. Baseline followed by annual ultrasounds were obtained during a median follow-up of 4.9 years.
RESULTS
Compared with standard care, insulin glargine reduced the primary CIMT outcome, but the difference was not statistically significant (difference = 0.0030 ± 0.0021 mm/year; P = 0.145) and significantly reduced the secondary CIMT outcomes (differences of 0.0033 ± 0.0017 mm/year [P = 0.049] and 0.0045 ± 0.0021 mm/year [P = 0.032], respectively). There were no differences in the primary and secondary outcomes between the n-3FA supplement and placebo groups.
CONCLUSIONS
In people with CV disease and/or CV risk factors and dysglycemia, insulin glargine used to target normoglycemia modestly reduced CIMT progression, whereas daily supplementation with n-3FA had no effect on CIMT progression. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1901064, encodeId=cc901901064c6, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Jun 18 11:41:00 CST 2013, time=2013-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636640, encodeId=fd17163664092, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jan 27 02:41:00 CST 2014, time=2014-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944342, encodeId=5475194434209, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Tue Sep 17 03:41:00 CST 2013, time=2013-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759257, encodeId=19ae1e5925706, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Aug 11 03:41:00 CST 2013, time=2013-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749396, encodeId=42371e49396a4, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Feb 09 13:41:00 CST 2014, time=2014-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393152, encodeId=6b661393152e5, content=<a href='/topic/show?id=eb2b6882506' target=_blank style='color:#2F92EE;'>#甘精胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68825, encryptionId=eb2b6882506, topicName=甘精胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Sat Apr 13 06:41:00 CST 2013, time=2013-04-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1901064, encodeId=cc901901064c6, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Jun 18 11:41:00 CST 2013, time=2013-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636640, encodeId=fd17163664092, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jan 27 02:41:00 CST 2014, time=2014-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944342, encodeId=5475194434209, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Tue Sep 17 03:41:00 CST 2013, time=2013-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759257, encodeId=19ae1e5925706, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Aug 11 03:41:00 CST 2013, time=2013-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749396, encodeId=42371e49396a4, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Feb 09 13:41:00 CST 2014, time=2014-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393152, encodeId=6b661393152e5, content=<a href='/topic/show?id=eb2b6882506' target=_blank style='color:#2F92EE;'>#甘精胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68825, encryptionId=eb2b6882506, topicName=甘精胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Sat Apr 13 06:41:00 CST 2013, time=2013-04-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1901064, encodeId=cc901901064c6, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Jun 18 11:41:00 CST 2013, time=2013-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636640, encodeId=fd17163664092, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jan 27 02:41:00 CST 2014, time=2014-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944342, encodeId=5475194434209, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Tue Sep 17 03:41:00 CST 2013, time=2013-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759257, encodeId=19ae1e5925706, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Aug 11 03:41:00 CST 2013, time=2013-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749396, encodeId=42371e49396a4, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Feb 09 13:41:00 CST 2014, time=2014-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393152, encodeId=6b661393152e5, content=<a href='/topic/show?id=eb2b6882506' target=_blank style='color:#2F92EE;'>#甘精胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68825, encryptionId=eb2b6882506, topicName=甘精胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Sat Apr 13 06:41:00 CST 2013, time=2013-04-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1901064, encodeId=cc901901064c6, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Jun 18 11:41:00 CST 2013, time=2013-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636640, encodeId=fd17163664092, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jan 27 02:41:00 CST 2014, time=2014-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944342, encodeId=5475194434209, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Tue Sep 17 03:41:00 CST 2013, time=2013-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759257, encodeId=19ae1e5925706, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Aug 11 03:41:00 CST 2013, time=2013-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749396, encodeId=42371e49396a4, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Feb 09 13:41:00 CST 2014, time=2014-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393152, encodeId=6b661393152e5, content=<a href='/topic/show?id=eb2b6882506' target=_blank style='color:#2F92EE;'>#甘精胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68825, encryptionId=eb2b6882506, topicName=甘精胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Sat Apr 13 06:41:00 CST 2013, time=2013-04-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1901064, encodeId=cc901901064c6, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Jun 18 11:41:00 CST 2013, time=2013-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636640, encodeId=fd17163664092, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jan 27 02:41:00 CST 2014, time=2014-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944342, encodeId=5475194434209, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Tue Sep 17 03:41:00 CST 2013, time=2013-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759257, encodeId=19ae1e5925706, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Aug 11 03:41:00 CST 2013, time=2013-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749396, encodeId=42371e49396a4, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Feb 09 13:41:00 CST 2014, time=2014-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393152, encodeId=6b661393152e5, content=<a href='/topic/show?id=eb2b6882506' target=_blank style='color:#2F92EE;'>#甘精胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68825, encryptionId=eb2b6882506, topicName=甘精胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Sat Apr 13 06:41:00 CST 2013, time=2013-04-13, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1901064, encodeId=cc901901064c6, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Jun 18 11:41:00 CST 2013, time=2013-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636640, encodeId=fd17163664092, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jan 27 02:41:00 CST 2014, time=2014-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944342, encodeId=5475194434209, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Tue Sep 17 03:41:00 CST 2013, time=2013-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759257, encodeId=19ae1e5925706, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Aug 11 03:41:00 CST 2013, time=2013-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749396, encodeId=42371e49396a4, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Feb 09 13:41:00 CST 2014, time=2014-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393152, encodeId=6b661393152e5, content=<a href='/topic/show?id=eb2b6882506' target=_blank style='color:#2F92EE;'>#甘精胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68825, encryptionId=eb2b6882506, topicName=甘精胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Sat Apr 13 06:41:00 CST 2013, time=2013-04-13, status=1, ipAttribution=)]

相关资讯

三项研究证明甘精胰岛素与癌症无关

费城(EGMN)——在美国糖尿病学会(ADA)2012科学年会上报告的3项大规模管理数据库分析研究一致表明,与其他类型的胰岛素相比,每日使用甘精胰岛素(来得时)不增加任何类型癌症的发病风险,包括乳腺癌、前列腺癌、结直肠癌、肺癌、胰腺癌或其他类型的癌症。法国里昂国际预防研究院院长Peter Boyle 博士在会上称,2009年有4篇论文同时提出了甘精胰岛素与癌症相关的担忧,之后研究者、医生和患者一直

NEJM:6年临床试验显示甘精胰岛素不会增加癌症风险(ORIGIN研究)

 居全球处方量首位的胰岛素甘精胰岛素是否与癌症有关联,一直为医生和患者所担心。近期揭晓的大规模糖尿病临床研究结果显示,与应用其他胰岛素相比,甘精胰岛素不会增加癌症风险。   这项名为“甘精胰岛素初始干预转归研究(ORIGIN)”的随机临床试验历时6年多,覆盖了包括中国在内的40个国家和地区,涉及1.25万名糖尿病患者,是有史以来最大规模的糖尿病临床研究项目。   研究结果显示,使用甘精胰岛素与

Diabetes Care:甘精胰岛素不增加肿瘤风险(法国研究)

  一项基于法国国家管理数据库的队列研究表明,在新开始基础胰岛素治疗的较大患者队列中,与使用其他基础胰岛素的患者相比,接受甘精胰岛素治疗的患者未发现恶性肿瘤风险增加。然而,由于随访时间不超过4年,进一步更长期的研究尤为必要。研究在2012年9月10日在线发表于《糖尿病护理》(Diabetes Care)杂志。  该研究旨在探讨与其他基础胰岛素相比,甘精胰岛素的使用与2型糖尿病患者的总体和

EASD年会:甘精胰岛素与乳腺癌无关

  新的流行病学数据再次表明,甘精胰岛素不会导致乳腺癌。该数据来自一项纳入约3,800例糖尿病女性患者的国际病例研究。   伦敦LA-SER生物医学研究咨询公司创始人Lucien Abenhaim博士在欧洲糖尿病研究协会(EASD)年会上报告称,这项旨在评估糖尿病女性患者使用甘精胰岛素与乳腺癌发病率相关性的研究显示,使用甘精胰岛素的糖尿病女性患者的乳腺癌发病率与使用其他类型胰岛素的患者并无差异。

Diabetes Care:艾塞那肽疗效安全性优于甘精胰岛素(IG)

  欧美学者的一项研究表明,接受每周一次艾塞那肽(EQW)治疗的患者在远期转归和安全性方面均优于甘精胰岛素(IG)治疗者。论文于2012年2月22日在线发表于《糖尿病治疗》(Diabetes Care)杂志。    研究者近期实施的一项研究表明,在单独服用二甲双胍或联用磺酰脲的2型糖尿病患者中,与每日应用IG相比,为期26周的EQW治疗在降低HbA1C、减少低血糖发生和进行性降低体重方

Baidu
map
Baidu
map
Baidu
map